Pharnext (PNEXF) News Today → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free PNEXF Stock Alerts $400.00 0.00 (0.00%) (As of 07/13/2023) Add Compare Share Share HeadlinesStock AnalysisHeadlinesStock AnalysisHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePHARNEXT: Pharnext takes full stock of its operating, strategic and financial situationfinanznachrichten.de - March 11 at 3:43 PMPharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1Aactusnews.com - February 28 at 11:05 AMPHARNEXT by Pharnext Stock (OTC:PNEXF), Insider Trading Activitybenzinga.com - February 25 at 11:58 PMPHARNEXT: Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1Afinanznachrichten.de - January 17 at 7:40 AMPharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1Aactusnews.com - January 17 at 7:40 AMPharnext set to release pivotal trial data for CMT1A treatment PXT3003investing.com - December 15 at 10:51 PMPharnext SA ALPHAmorningstar.com - December 2 at 12:23 PMPHARNEXT: Pharnext announces successful manufacturing of registration batches of PXT3003 in the United Statesfinanznachrichten.de - November 20 at 9:37 AMPharnext announces successful manufacturing of registration batches of PXT3003 in the United Statesactusnews.com - November 20 at 9:37 AMPharnext received two offers valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR 250m, and raises EUR 2.5mactusnews.com - October 16 at 6:57 PMPharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)actusnews.com - September 28 at 9:13 AMPHARNEXT: Pharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Boardfinanznachrichten.de - July 10 at 10:26 AMPharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Boardactusnews.com - July 10 at 10:26 AMPharnext appoints Gilbert Wagener, M.D., Ph.D. as Chief Medical Officeractusnews.com - June 15 at 12:15 PMPharnext supports and participates in the First European Charcot-Marie-Tooth disease Specialists Conferenceactusnews.com - June 8 at 7:12 AMPHARNEXT: Edison Investment Research publishes updates research report on Pharnextfinanznachrichten.de - May 22 at 7:39 AMPHARNEXT: Pharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)finanznachrichten.de - May 12 at 8:19 AMPharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)actusnews.com - May 12 at 8:19 AMGlobal Dental Partnering 2010-2023: Deal Trends, Players and Financialsfinance.yahoo.com - May 5 at 4:15 PMPharnext supports the online 2023 Conference of CMTUK, the UK's Charity dedicated to supporting people living with Charcot-Marie-Tooth diseaseactusnews.com - April 18 at 7:25 AMPHARNEXT: Pharnext supports and participates in two congresses on Neuromuscular Disorders in Europefinanznachrichten.de - March 20 at 8:20 AMPharnext supports and participates in two congresses on Neuromuscular Disorders in Europeactusnews.com - March 20 at 8:20 AMPharnext supports and participates in two congresses dedicated to Charcot-Marie-Tooth diseases in Marseille, Franceactusnews.com - March 14 at 3:49 AMPHARNEXT: Pharnext supports and participates in the 27th edition of the Francophone Peripheral Nerve Society conference (SFNP) in Parisfinanznachrichten.de - March 6 at 5:02 AMPharnext SA (ALPHA.PA)finance.yahoo.com - February 15 at 10:51 PMPharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1Aactusnews.com - February 2 at 7:20 AMPHARNEXT: Pharnext announces successful completion of manufacturing transfer and scale-up of PXT3003 in the United Statesfinanznachrichten.de - January 26 at 8:15 AMPHARNEXT: Pharnext supports and participates in the 21st King's College Symposium on Neuromuscular Diseases in Londonfinanznachrichten.de - January 25 at 7:34 AMPHARNEXT: Pharnext convenes its shareholders to approve a new legal and financial framework adapted to its missionfinanznachrichten.de - January 24 at 5:54 AMPHARNEXT: Agreement signed for the financing of Pharnext by Néovacsfinanznachrichten.de - January 19 at 8:03 AMSignature d'une convention encadrant le financement de Pharnext par Néovacsactusnews.com - January 19 at 8:03 AMAgreement signed for the financing of Pharnext by Néovacsactusnews.com - January 19 at 8:03 AMPHARNEXT: Shareholder Letter: "Time to reveal Pharnext true value"finanznachrichten.de - January 11 at 8:34 AMShareholder Letter: 'Time to reveal Pharnext true value'actusnews.com - January 11 at 8:34 AMPHARNEXT: Pharnext in discussions with investment research firm Edison to update valuation of assetsfinanznachrichten.de - January 5 at 8:51 AMPharnext in discussions with investment research firm Edison to update valuation of assetsactusnews.com - January 5 at 8:51 AMPharnext strengthens its ties with Néovacs to -2-finanznachrichten.de - December 28 at 5:42 PMPharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Developmentbenzinga.com - December 28 at 5:42 PMPharnext Reports First Half 2022 Financial Resultsfinance.yahoo.com - October 17 at 8:09 AMPharnext appoints former Silence Therapeutics exec as CFOseekingalpha.com - September 2 at 10:33 PMPharnext to raise €2.5M loan from French biotech Néovacsseekingalpha.com - August 25 at 12:30 AMPharnext Announces a EUR2.5m Loan Agreement with Néovacsfinanznachrichten.de - August 24 at 2:22 PMPharnext Announces a €2.5m Loan Agreement with Néovacsfinance.yahoo.com - August 23 at 5:30 AMPharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directorsca.finance.yahoo.com - July 13 at 10:39 AMPharnext Appoints Antoine Gravelle as General Counseluk.finance.yahoo.com - July 5 at 4:54 AMPharnext Announces Successful Debt Refinancing and New Loan Agreementuk.finance.yahoo.com - June 8 at 4:46 AMPharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updatesfinanznachrichten.de - April 25 at 8:48 PMPharnext: Pharnext Reports Full Year 2021 -2-finanznachrichten.de - April 25 at 8:48 PMJoshua Schafer Appointed as Interim Chairman of Pharnext Board of Directorsapnews.com - March 30 at 3:27 PMExperienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directorsfinance.yahoo.com - December 23 at 7:34 AM Get Pharnext News Delivered to You Automatically Sign up to receive the latest news and ratings for PNEXF and its competitors with MarketBeat's FREE daily newsletter. Email Address “Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. PNEXF Media Mentions By Week PNEXF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PNEXF News Sentiment▼0.000.37▲Average Medical News Sentiment PNEXF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PNEXF Articles This Week▼00▲PNEXF Articles Average Week Get Pharnext News Delivered to You Automatically Sign up to receive the latest news and ratings for PNEXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PNEXF) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharnext SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
